• +1-646-491-9876
    • +91-20-67278686

    Search

    Dermatomyositis-Pipeline Review H1 2017

    Dermatomyositis-Pipeline Review H1 2017

    • Report Code ID: RW0001834336
    • Category Pharmaceuticals
    • No. of Pages 105
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Dermatomyositis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Dermatomyositis - Pipeline Review, H1 2017, provides an overview of the Dermatomyositis (Musculoskeletal Disorders) pipeline landscape.

    Dermatomyositis is a rare inflammatory disease which is characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Dermatomyositis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dermatomyositis (Musculoskeletal Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Dermatomyositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 3 and 2 respectively.

    Dermatomyositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Dermatomyositis (Musculoskeletal Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Dermatomyositis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Dermatomyositis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Dermatomyositis (Musculoskeletal Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Dermatomyositis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Dermatomyositis - Overview
    Dermatomyositis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Dermatomyositis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Dermatomyositis - Companies Involved in Therapeutics Development
    Eli Lilly and Company
    F. Hoffmann-La Roche Ltd
    Hope Pharmaceuticals Inc
    Idera Pharmaceuticals Inc
    KPI Therapeutics Inc
    Marathon Pharmaceuticals LLC
    MedImmune LLC
    Neovacs SA
    Novartis AG
    Octapharma AG
    Pfizer Inc
    Dermatomyositis - Drug Profiles
    anabasum - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    baricitinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dalazatide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    immune globulin (human) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IMO-8400 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MEDI-7734 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MP-117 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    siponimod - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sodium thiosulfate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tocilizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tofacitinib citrate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target IFN-Alpha for Metabolic Disorders, Immunology, Infectious Diseases and Musculoskeletal Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Dermatomyositis - Dormant Projects
    Dermatomyositis - Product Development Milestones
    Featured News & Press Releases
    May 17, 2017: FDA Grants Octapharma USA Orphan Drug Designation for Octagam 10% for the Treatment of Dermatomyositis
    May 11, 2017: Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Anabasum for the Treatment of Skin-Predominant Dermatomyositis
    May 04, 2017: Neovacs to present clinical development update on IFNalpha Kinoid in dermatomyosis
    Mar 09, 2017: Neovacs to present IFNalpha Kinoid technology and its clinical outlooks at upcoming Keystone Symposia Conference
    Feb 09, 2017: Neovacs Issued New Broad Patent in China for IFNa Kinoid
    Nov 29, 2016: Corbus Pharmaceuticals Commences One-Year Open-Label Extension to its Ongoing Phase 2 Study of Resunab (JBT-101) for Skin-Predominant Dermatomyositis
    Sep 28, 2016: Corbus Announces Data on Effects of Resunab (JBT-101) in a Clinical Research Model of Resolution of Inflammation
    Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis
    Oct 13, 2015: Corbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum
    Aug 06, 2015: Corbus Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 13, 2015
    Jul 13, 2015: Corbus Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Resunab for the Treatment of Dermatomyositis
    Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis
    Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis
    Jun 05, 2015: Corbus Pharmaceuticals Expands Clinical Development of Resunab With a Phase 2 Trial for the Treatment of Rare Disease Dermatomyositis
    May 13, 2015: Neovacs granted 1.8 million euros in research tax credit
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Dermatomyositis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Dermatomyositis - Pipeline by Eli Lilly and Company, H1 2017
    Dermatomyositis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Dermatomyositis - Pipeline by Hope Pharmaceuticals Inc, H1 2017
    Dermatomyositis - Pipeline by Idera Pharmaceuticals Inc, H1 2017
    Dermatomyositis - Pipeline by KPI Therapeutics Inc, H1 2017
    Dermatomyositis - Pipeline by Marathon Pharmaceuticals LLC, H1 2017
    Dermatomyositis - Pipeline by MedImmune LLC, H1 2017
    Dermatomyositis - Pipeline by Neovacs SA, H1 2017
    Dermatomyositis - Pipeline by Novartis AG, H1 2017
    Dermatomyositis - Pipeline by Octapharma AG, H1 2017
    Dermatomyositis - Pipeline by Pfizer Inc, H1 2017
    Dermatomyositis - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Dermatomyositis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Eli Lilly and Company
    F. Hoffmann-La Roche Ltd
    Hope Pharmaceuticals Inc
    Idera Pharmaceuticals Inc
    KPI Therapeutics Inc
    Marathon Pharmaceuticals LLC
    MedImmune LLC
    Neovacs SA
    Novartis AG
    Octapharma AG
    Pfizer Inc

    Request for Sample

    Report Url https://www.reportsweb.com//dermatomyositis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//dermatomyositis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//dermatomyositis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments